Icagen, Pfizer Ink Compound Discovery Deal

Icagen announced that it has entered into a worldwide collaboration and licensing agreement with Pfizer for the discovery, development and commercialization of compounds that modulate three specific sodium ion channels as new potential treatments for pain and related disorders.

Under the terms of the agreement, Icagen and Pfizer said they will identify compounds that target these three ion channels.

The companies added they will form a joint research committee to monitor and oversee the collaboration.

Pfizer said that it will fund all aspects of the collaboration, including the research and preclinical development efforts at Icagen, and will have exclusive worldwide rights to commercialize products that result from the collaboration.